Neos Therapeutics Inc. (NASDAQ:NEOS) shares saw unusually-strong trading volume on Friday . Approximately 142,987 shares traded hands during trading, an increase of 8% from the previous session’s volume of 132,912 shares.The stock last traded at $8.46 and had previously closed at $8.50.

Several equities analysts recently commented on NEOS shares. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Royal Bank Of Canada dropped their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, May 17th. Finally, BMO Capital Markets started coverage on shares of Neos Therapeutics in a research report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price target for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $21.75.

The firm’s market capitalization is $137.18 million. The stock has a 50 day moving average of $9.71 and a 200-day moving average of $10.04.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.08. On average, equities research analysts forecast that Neos Therapeutics Inc. will post ($4.88) EPS for the current fiscal year.

In other Neos Therapeutics news, Director Alan L. Heller acquired 10,000 shares of the stock in a transaction dated Thursday, May 19th. The shares were bought at an average price of $7.61 per share, with a total value of $76,100.00. Following the purchase, the director now directly owns 379,888 shares of the company’s stock, valued at approximately $2,890,947.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gregory J. Robitaille acquired 7,442 shares of the stock in a transaction dated Wednesday, May 18th. The stock was acquired at an average cost of $7.55 per share, for a total transaction of $56,187.10. Following the purchase, the director now directly owns 55,677 shares in the company, valued at $420,361.35. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP boosted its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.